中华医学杂志
中華醫學雜誌
중화의학잡지
National Medical Journal of China
2013年
46期
3663-3666
,共4页
何英剑%李金锋%王天峰%解云涛%范照青%王立泽%英旻%欧阳涛
何英劍%李金鋒%王天峰%解雲濤%範照青%王立澤%英旻%歐暘濤
하영검%리금봉%왕천봉%해운도%범조청%왕립택%영민%구양도
乳腺肿瘤%分子亚型%生存%受体%淋巴结
乳腺腫瘤%分子亞型%生存%受體%淋巴結
유선종류%분자아형%생존%수체%림파결
Breast neoplasms%Molecular subtypes%Survival%Receptor%Lymph nodes
目的 探讨不同分子亚型浸润性乳腺癌的治疗后生存情况.方法 采用回顾性分析,收集2000年1月至201 1年7月在北京肿瘤医院乳腺癌预防治疗中心确诊并在本院完成治疗4491例浸润性乳腺癌病例,根据病例的激素受体状态(HR)、人类表皮生长因子受体2(HER2)的免疫组织化学结果(HER2++的患者进行了FISH检测),将所有病例分为:HR +/HER2-、HER2阳性及HR-/HER2-3个亚型,分析不同分子亚型乳腺癌治疗后生存情况,并分析各分子亚型在不同淋巴结状态下的生存情况.结果 HR +/HER2-(2504例)、HER2阳性(680例)及HR-/HER2-型(1085例)的3年无复发生存(RFS)率分别为94.9％、89.5％与92.3％,生存曲线之间的差异有统计学意义,P =0.0001;淋巴结阳性与淋巴结阴性的3年RFS率分别为87.1％与97.8％,生存曲线之间的差异有统计学意义,P＜0.01;淋巴结阴性组3种亚型的乳腺癌RFS生存曲线间的差异无统计学意义,P =0.102;而在淋巴结阳性组HR +/HER2-型的RFS明显优于HR-/HER2-型与HER-2阳性型,生存曲线之间的差异有统计学意义,P =0.001.结论 不同分子亚型乳腺癌的治疗后生存情况不同,淋巴结状态可能是更重要的影响因素.
目的 探討不同分子亞型浸潤性乳腺癌的治療後生存情況.方法 採用迴顧性分析,收集2000年1月至201 1年7月在北京腫瘤醫院乳腺癌預防治療中心確診併在本院完成治療4491例浸潤性乳腺癌病例,根據病例的激素受體狀態(HR)、人類錶皮生長因子受體2(HER2)的免疫組織化學結果(HER2++的患者進行瞭FISH檢測),將所有病例分為:HR +/HER2-、HER2暘性及HR-/HER2-3箇亞型,分析不同分子亞型乳腺癌治療後生存情況,併分析各分子亞型在不同淋巴結狀態下的生存情況.結果 HR +/HER2-(2504例)、HER2暘性(680例)及HR-/HER2-型(1085例)的3年無複髮生存(RFS)率分彆為94.9％、89.5％與92.3％,生存麯線之間的差異有統計學意義,P =0.0001;淋巴結暘性與淋巴結陰性的3年RFS率分彆為87.1％與97.8％,生存麯線之間的差異有統計學意義,P＜0.01;淋巴結陰性組3種亞型的乳腺癌RFS生存麯線間的差異無統計學意義,P =0.102;而在淋巴結暘性組HR +/HER2-型的RFS明顯優于HR-/HER2-型與HER-2暘性型,生存麯線之間的差異有統計學意義,P =0.001.結論 不同分子亞型乳腺癌的治療後生存情況不同,淋巴結狀態可能是更重要的影響因素.
목적 탐토불동분자아형침윤성유선암적치료후생존정황.방법 채용회고성분석,수집2000년1월지201 1년7월재북경종류의원유선암예방치료중심학진병재본원완성치료4491례침윤성유선암병례,근거병례적격소수체상태(HR)、인류표피생장인자수체2(HER2)적면역조직화학결과(HER2++적환자진행료FISH검측),장소유병례분위:HR +/HER2-、HER2양성급HR-/HER2-3개아형,분석불동분자아형유선암치료후생존정황,병분석각분자아형재불동림파결상태하적생존정황.결과 HR +/HER2-(2504례)、HER2양성(680례)급HR-/HER2-형(1085례)적3년무복발생존(RFS)솔분별위94.9％、89.5％여92.3％,생존곡선지간적차이유통계학의의,P =0.0001;림파결양성여림파결음성적3년RFS솔분별위87.1％여97.8％,생존곡선지간적차이유통계학의의,P＜0.01;림파결음성조3충아형적유선암RFS생존곡선간적차이무통계학의의,P =0.102;이재림파결양성조HR +/HER2-형적RFS명현우우HR-/HER2-형여HER-2양성형,생존곡선지간적차이유통계학의의,P =0.001.결론 불동분자아형유선암적치료후생존정황불동,림파결상태가능시경중요적영향인소.
Objective To explore the survival status after treatment for patients with different molecular subtypes of breast cancers.Methods A total of 4491 patients with invasive breast cancer from January 2000 to July 2011 were retrospectively recruited to receive pathological verification and treatment at our clinic.According to the immunohistochemical results of hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2),they were assigned into 3 groups of HR +/HER2-,HER2 + and HR-/ HER2-.Survival analyses were conducted to examine the effects of molecular subtypes and lymph node status on survival.Results The 3-year recurrence free survival for HR +/HER2-,HER2 + and HR-/ HER2-were 94.9％,89.5％ ane 92.3％ respectively.Different molecular subtypes presented different survival patterns (P =0.0001).The 3-year recurrence-free survival (RFS) for LN + and LN-was 87.1％ and 97.8％ respectively.And statistical difference existed (P ＜ 0.01).No difference was detected among three molecular subtypes of LN-(P =0.102) ; However,for LN + patients,HR +/HER2-showed a higher RFS than HER2 + and HR-/HER2 (P =0.001).Conclusion Different molecular subtypes of breast cancers have varying survival.And lymph node status is probably an important prognostic factor.
